title: TACE combined with dendritic cells and cytokine-induced killer cells in the treatment of hepatocellular carcinoma: A meta-analysis.
abstract: Patients with hepatocellular carcinoma (HCC), a fatal cancer, have benefited significantly from TACE (transcatheter arterial chemoembolization) and immunotherapy treatments. Immunotherapy that includes dendritic cells and cytokine-induced killer cells (DC-CIK) in combination with TACE has been extensively applied in cases of HCC. Few decisive conclusions about these combined effects on the outcomes of HCC patients have been reached. Therefore, the present meta-analysis was performed to compare the efficacy of the combined usage of DC-CIK with TACE with a TACE therapy alone on the outcomes of HCC patients. Participants were enrolled in eight eligible trials. The efficiency and safety of TACE followed by DC-CIK immunotherapy (experimental group) and of TACE alone (control group) were compared. The meta-analysis results demonstrated that TACE plus DC-CIK immunotherapy is possibly superior to TACE alone in promoting a better overall response, for half-year, 1-year, and 2-year overall survival (OS), median overall survival (OS) and progression-free survival rates (PFS) in HCC patients. Further studies should be performed to confirm the effect of the combined therapy.
authors.affiliation: Department of Ultrasound, Shenzhen Guangming New District People's Hospital, 339# Songbai road, Gongming Street, Shenzhen 518106, China.
authors.forename: Guangzhi
authors.initials: G
authors.lastname: He
authors.affiliation: No. 2 Clinic, Logistic Support Department, Central Military Commission, People's Republic of China, Beijing 100071, China.
authors.forename: Chenhong
authors.initials: C
authors.lastname: Zheng
authors.affiliation: Department of Ultrasound, Shenzhen Guangming New District People's Hospital, 339# Songbai road, Gongming Street, Shenzhen 518106, China.
authors.forename: Huiping
authors.initials: H
authors.lastname: Huo
authors.affiliation: No. 2 Clinic, Logistic Support Department, Central Military Commission, People's Republic of China, Beijing 100071, China.
authors.forename: Huiming
authors.initials: H
authors.lastname: Zhang
authors.affiliation: No. 2 Clinic, Logistic Support Department, Central Military Commission, People's Republic of China, Beijing 100071, China.
authors.forename: Zhiquan
authors.initials: Z
authors.lastname: Zhu
authors.affiliation: Department of Ultrasound, South Building, Chinese PLA General Hospital, 28 Fuxing Road, Beijing 100853, China.
authors.forename: Junlai
authors.initials: J
authors.lastname: Li
authors.affiliation: Department of Vascular and Endovascular Surgery, Chinese PLA General Hospital, Beijing, 100853, PR China. Electronic address: zhanghongpeng@263.net.
authors.forename: Hongpeng
authors.initials: H
authors.lastname: Zhang
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000628:therapy*; D057785:Catheters / Q000706:statistics & numerical data; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D055612:Cytokine-Induced Killer Cells / Q000276:immunology / Q000637:transplantation*; D003713:Dendritic Cells / Q000276:immunology / Q000637:transplantation*; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D008113:Liver Neoplasms / Q000401:mortality / Q000628:therapy*; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents
keywords: DC-CIK; Hepatocellular carcinoma; Immunotherapy; Meta-analysis; TACE